Stockscreener 앱 받기
8.55
1.91%
0.16
시간 외 거래:
8.61
0.06
+0.70%
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
PHAT|Phathom Pharmaceuticals Inc|Price:11.950|Chg%:+0.510 - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence - TradingKey
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals (PHAT) to Post Earnings on Thursday - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY) - The Globe and Mail
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25 - Moomoo
PHAT Stock Price, Quote & Chart - ChartMill
Millennium group discloses 4.2% Phathom (PHAT) stake in amended ownership filing - Stock Titan
Avoiding Lag: Real-Time Signals in (PHAT) Movement - Stock Traders Daily
Phathom Pharmaceuticals to announce Q2 2026 financial results - scanx.trade
Phathom Pharmaceuticals schedules Q2 2026 earnings call for July 30 - Traders Union
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 - The Manila Times
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business ... - Caledonian Record
Phathom Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Phathom plans July 30 update on its gastrointestinal treatments - Stock Titan
Phathom Pharmaceuticals expands Medical Science Liaison hiring drive across U.S. - Traders Union
Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) officer surrenders 1,555 for tax withholding - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Jul 2026 $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Gains 1.6% as Biotech Stock Approaches Key ResistanceBear Pennant - Bölüm Sonu Canavarı
Enterprise value to EBITDA forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
Price to book forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
Price to sales forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
PHATPhathom Pharmaceuticals Inc Revenue Breakdown - Finviz
Phathom Pharmaceuticals advances pivotal EoE acid suppression study to next stage - Traders Union
Discipline and Rules-Based Execution in PHAT Response - Stock Traders Daily
Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT) - TradingView
PHAT Forecast — Price Target — Prediction for 2027 - TradingView
Phathom Pharmaceuticals supports upcoming GI meetings as industry engagement expands - Traders Union
Phathom Pharmaceuticals details new Voquezna launch pace, shares track gastro health focus - Ad-hoc-news.de
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - Moomoo
Phathom Pharmaceuticals (PHAT) Completes Enrollment in Clinical Trial - GuruFocus
Phathom completes enrollment in vonoprazan trial for EoE By Investing.com - Investing.com Australia
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study - Investing.com UK
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com - Investing.com Nigeria
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial - TipRanks
Phathom Pharmaceuticals Completes Enrollment in Phase 2 VOQUEZNA Clinical Trial for Eosinophilic Esophagitis, Results Expected Q4 2026 5 – Minichart - Minichart
Phathom completes enrollment in vonoprazan trial for EoE - Investing.com
Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026 - Stock Titan
Phathom Pharmaceuticals Completes Patient Enrollment Ahead - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - The Manila Times
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven? - 富途牛牛
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
1.84%
0.86%
자본화:
|
볼륨(24시간):